Biodexa Pharmaceuticals (BDRX) Beginning Cash Balance (2019 - 2022)

Biodexa Pharmaceuticals (BDRX) has 4 years of Beginning Cash Balance data on file, last reported at $11.8 million in Q4 2022.

• For the quarter ending Q4 2022, Beginning Cash Balance rose 15.97% year-over-year to $11.8 million; the trailing twelve-month figure through Dec 2022 stood at $44.9 million (down 8.1% YoY), and the FY2022 full-year result was $12.4 million, up 19.88% from the prior year.
• Beginning Cash Balance slipped to $11.8 million in Q4 2022, from $12.4 million in the prior quarter.
• In the past five years, Beginning Cash Balance ranged from a high of $14.4 million in Q4 2020 to a low of $3.0 million in Q4 2019.
• A 4-year average of $10.9 million and a median of $11.8 million in 2022 frame the typical range for Beginning Cash Balance.
• Across the five-year window, Beginning Cash Balance jumped 379.01% in 2020 and dropped 29.51% in 2021, its largest moves.
• Tracing BDRX's Beginning Cash Balance over 4 years: stood at $3.0 million in 2019, then jumped by 379.01% to $14.4 million in 2020, then dropped by 29.51% to $10.2 million in 2021, then rose by 15.97% to $11.8 million in 2022.
• Business Quant data shows BDRX's Beginning Cash Balance at $11.8 million in Q4 2022, $12.4 million in Q3 2022, and $10.2 million in Q4 2021.